D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

Key Points

• D. Boral Capital reiterated a Buy rating on Trevi Therapeutics with a $19.00 price target, implying roughly a 25.45% upside from the stock's current level.
• Market consensus remains a Buy (two Strong Buy, nine Buy, one Sell) with a consensus price target of $21.60 as multiple firms issued or adjusted price targets and ratings recently.
• Shares traded up to $15.15 (about +4.2%) with a market cap of $1.95 billion; the company beat quarterly EPS expectations (‑$0.06 vs. ‑$0.10) and institutional investors hold roughly 95.8% of the stock.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "buy" rating reiterated by analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $19.00 price target on the stock. D. Boral Capital's price target would indicate a potential upside of 25.45% from the stock's current price.

Several other research analysts have also issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, March 9th. JonesTrading dropped their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Thursday, March 19th. Morgan Stanley dropped their price target on shares of Trevi Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, March 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Finally, Needham & Company LLC increased their price target on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Trevi Therapeutics has a consensus rating of "Buy" and a consensus price target of $21.60.

Trevi Therapeutics Trading Up 4.2%

NASDAQ:TRVI traded up $0.61 during mid-day trading on Friday, hitting $15.15. The company's stock had a trading volume of 4,811,555 shares, compared to its average volume of 1,409,564. Trevi Therapeutics has a fifty-two week low of $5.38 and a fifty-two week high of $15.76. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -47.41 and a beta of 0.99. The stock has a fifty day moving average of $11.75 and a 200-day moving average of $11.51.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. On average, equities analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several large investors have recently added to or reduced their stakes in TRVI. AQR Capital Management LLC grew its stake in shares of Trevi Therapeutics by 20.4% during the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company's stock valued at $174,000 after purchasing an additional 4,688 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Trevi Therapeutics by 31.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company's stock valued at $278,000 after acquiring an additional 10,445 shares during the last quarter. Millennium Management LLC boosted its stake in Trevi Therapeutics by 356.3% in the first quarter. Millennium Management LLC now owns 823,249 shares of the company's stock valued at $5,178,000 after acquiring an additional 642,830 shares during the last quarter. Strs Ohio acquired a new position in shares of Trevi Therapeutics in the 1st quarter valued at $52,000. Finally, Creative Planning lifted its stake in shares of Trevi Therapeutics by 17.5% in the 2nd quarter. Creative Planning now owns 20,247 shares of the company's stock valued at $111,000 after purchasing an additional 3,016 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.